2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on Classical Hodgkin Lymphoma: Does Pembrolizumab Improve PFS vs. Brentuximab Vedotin in Patients With Relapsed/Refractory Disease?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jakub Svoboda
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Jakub Svoboda
140 views
August 6, 2020
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology